<DOC>
	<DOC>NCT01046266</DOC>
	<brief_summary>This open-label study will assess the pharmacodynamics, safety and efficacy of RO5083945 as compared to cetuximab in patients with head and neck squamous cell carcinoma. Patients will receive at least 2 infusions of either RO5083945 or cetuximab. Anticipated time on study treatment is up to 3 months, and target sample size is &lt;50.</brief_summary>
	<brief_title>A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>adult patients, &gt;/=18 years of age squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx carcinoma of nasal cavity, paranasal sinus and nasopharynx recurrent squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx known positivity for HIV, hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>